@avacta's AVA6000 approved by MHRA. Superb news. First dosing 'around mid-year'; first data to come within 3-4 months after that.

A summary thread on the significance of AVA6000 - and #AVCT's pre CISION platform as a whole - to both the oncology industry and to AVCT itself. 1/10

In very basic terms, #AVCT's pre CISION chemotherapies are essentially reformulated versions of existing, approved chemotherapies that have been used on cancer patients for many years - decades, even.

The pre CISION tech is simply an attempt to improve the safety profile... 2/10

...of the chemo.

Most therapeutics going through clinical trials look for an improvement of at least 20% over the existing industry-standard drug. A 50% increase in efficacy would usually be considered an astonishing result.

In pre-clinical mouse models for #AVCT's AVA6000 3/10

...18 times more pro-doxorubicin was found in the tumour than in the heart. Compare that to the 1:1 ratio of the standard doxorubicin.

What this means is that the pre CISION tech could be used to enable the giving of doses to patients that are multiple times more potent... 4/10

...than standard chemotherapy drugs - either in the form of greater number of cycles of chemo, or in the potency of the individual dose.

For example, in #AVCT's pre-clinical trials, pro-dox (AVA6000) doses were 6x more potent than the standard dox doses.

The results? The...5/10